Emma Jo Steckler, CF, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2625 N 19th St, Bismarck, ND 58503 Phone: 701-222-3175 Fax: 701-222-3186 |
Madison Kurle Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 806 N Washington St, Bismarck, ND 58501 Phone: 701-323-4028 |
Christen Carufel Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 720 N 14th St, Bismarck, ND 58501 Phone: 701-323-4028 |
Michelle Burns Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6176 |
Mercedes Oberlander Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1615 Capitol Way, Bismarck, ND 58501 Phone: 701-751-0410 |
Emma Peterson, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4530 Northern Sky Dr, Bismarck, ND 58503 Phone: 701-751-6336 |
Mrs. Kathryn Jean Kringstad, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 806 N Washington St, Bismarck, ND 58501 Phone: 701-323-4028 |
Rachel Christine Petit, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1107 S 7th St, Bismarck, ND 58504 Phone: 701-323-4650 |
Wyniah Lyn Mintz, MS, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 809 W Interstate Ave, Bismarck, ND 58503 Phone: 701-323-6097 |
Liana Watson Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2625 N 19th St, Bismarck, ND 58503 Phone: 701-222-3175 Fax: 701-222-3186 |
Mrs. Hannah Mcdonald, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2625 N 19th St, Bismarck, ND 58503 Phone: 701-222-3175 Fax: 701-222-3186 |
Deborah K Isaacson, MS/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6198 |
Ava Burckhard, CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 4501 Coleman St N Suite #103, Pediatric Therapy Partners, Bismarck, ND 58503 Phone: 701-751-6336 |
Breanna Donarski Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 4580 Coleman St, Bismarck, ND 58503 Phone: 701-751-4224 |
Briona Thielen Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 806 N Washington St, Bismarck, ND 58501 Phone: 701-323-4029 |
Shanna Crouse Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3400 E Calgary Ave, Bismarck, ND 58503 Phone: 701-989-2567 |
Chelsie Lynn Getzlaff, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12700 11th Ave Sw, Burlington, ND 58722 Phone: 701-720-5381 |
Mrs. Mandy Dawn Lemer, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 301 Wallace Street, Burlington, ND 58722 Phone: 701-839-7135 |
Mrs. Londa Lenae Pedersen, M.S Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7080 8th Ave, Cannon Ball, ND 58528 Phone: 701-854-3341 |
Mrs. Kelly Marie Rosenau, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 3rd Ave S, Carrington, ND 58421 Phone: 701-652-3136 |
News Archive
Anti-tobacco efforts by U.S. states were "abysmal" last year as their collective spending on anti-smoking programs declined 11 percent and only two raised cigarette taxes, the American Lung Association said. While more than half the states already ban the use of cigarettes in restaurants, bars and workplaces, no additional states passed comprehensive anti-smoking laws last year, the Washington-based health advocacy group said today in a report.
A new study in the Journal of Nutrition Education and Behavior, published by Elsevier, explores real-time personal and employee safety experiences and perspectives of school nutrition professionals ranging from frontline staff to state leadership across the United States during the early weeks of the coronavirus pandemic.
BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.
Healthcare facilities sometimes lack the appropriate equipment and supplies to successfully manage an emergency in their facility in a timely manner, according to data released today by the Pennsylvania Patient Safety Authority and published in the June Pennsylvania Patient Safety Advisory.
› Verified 8 days ago